Business Context and Reporting Period
Company: U.S. Physical Therapy, Inc. (USPH)
Filing Type: Form 8-K (Current Report)
Date of Report: March 26, 2025
Subject: Approval of new compensatory arrangements for senior management effective March 26, 2025.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on the terms of executive compensation plans.
Material Changes
The primary material change is the adoption of four new incentive plans for senior management, replacing or supplementing prior arrangements. These plans tie executive compensation to the achievement of Adjusted EBITDA targets and individual performance goals for the 2025 fiscal year.
Guidance, Outlook, and Management Commentary
Compensatory Arrangements Approved:
The Compensation Committee approved the following plans for the CEO, President, CFO, COO West, and EVP:
- Objective Long-Term Incentive Plan (LTIP): Potential Restricted Stock Awards (RSAs) granted in Q1 2026 based on 2025 Adjusted EBITDA. Vesting occurs over 16 quarters (May 2026 to March 2030). Maximum potential awards: CEO (12,500 shares), President (7,500 shares), CFO/COO West/EVP (5,000 shares each).
- Discretionary LTIP: Additional RSAs granted in Q1 2026 based on individual and corporate performance evaluation. Vesting schedule matches the Objective LTIP. Maximum potential awards mirror the Objective LTIP.
- Objective Bonus Plan: Cash or RSAs awarded in Q1 2026 based on Adjusted EBITDA. Target is up to 100% of base salary for the CEO and up to 75% for other executives.
- Discretionary Bonus Plan: Cash or RSAs awarded based on individual goals. Target is up to 50% of base salary.
Conditions: All awards require continuous employment through the grant date or December 31, 2025, depending on the plan. The Committee retains sole discretion on award amounts and types (cash vs. stock).
Investor Verification Checklist
- Verify the specific Adjusted EBITDA targets required to trigger the Objective LTIP and Objective Bonus Plan.
- Review the full text of Exhibits 99.1 through 99.4 for detailed vesting acceleration clauses and forfeiture conditions.
- Confirm the total potential equity dilution from the maximum RSA grants (up to 35,000 shares across all executives per plan).
- Monitor Q1 2026 announcements for the actual grant of RSAs and cash bonuses based on 2025 performance.